Venous stasis

La Jolla Vein & Vascular Adds New Medical Specialty; Opens Dermatology Clinic in Vista

Retrieved on: 
星期四, 二月 15, 2024
Health, General Health, Skin cancer, Psoriasis, Infection, Medicine, Suite, Multimedia, MD, Moles, Venous stasis, Skin, Rash, Dermatology, UC, Varicose veins, Rosacea, Psychology, Patient, Knowledge, Dermatitis, Lipoma, Environment, Medical imaging

La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.

Key Points: 
  • La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.
  • The dermatology clinic is set to open in March, and is located at 906 Sycamore Ave, Suite 100, Vista, California.
  • View the full release here: https://www.businesswire.com/news/home/20240215088694/en/
    Dr. Heidi Busch, a board-certified dermatologist joins La Jolla Vein & Vascular to spearhead their expansion of services with a new Medical and Cosmetic Dermatology clinic in Vista, California.
  • To schedule a consultation with Dr. Busch, call 760-249-7007 or learn more about La Jolla Vein & Vascular’s services at www.ljvascular.com .

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis

Retrieved on: 
星期三, 一月 31, 2024
Streptomyces, Fungal infection, Investigational New Drug, Venous stasis, Nail disease, Prevalence, IND, HDAC, Dermatophytosis, FDA, Ciclopirox, Onycholysis, Food, Vanda, Onychomycosis, Fungus, Antibiotics

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Key Points: 
  • WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
  • Onychomycosis, or tinea unguium, is a fungal infection of the nail.
  • Onychomycosis can result in discoloration of the nail, onycholysis (nail separation from the nail bed), and nail plate thickening.
  • There have not been any new onychomycosis treatments approved by the FDA since 2014.4
    Centers for Disease Control and Prevention.

ManaMed's Cutting-Edge PlasmaFlow Device Receives UnitedHealthcare Coverage Based Upon Medical Necessity

Retrieved on: 
星期四, 十月 13, 2022
Pressure, Time-invariant system, Risk, Pulmonary embolism, Bleeding, Velcro, Intermittent pneumatic compression, Policy, Patient, CMS, IPC, DVT, Technology, Venous stasis, CEO, UnitedHealth Group, Awareness, Safety, UHC, Manam Motu, Contraindication, FDA, Venous thrombosis, Birth control, Pharmaceutical industry

DENTON, Texas, Oct. 13, 2022 /PRNewswire/ -- ManaMed strives to be at the forefront of medical innovation, which is why it is excited to announce that its DVT prevention device, PlasmaFlow, has just received UnitedHealthcare coverage.

Key Points: 
  • DENTON, Texas, Oct. 13, 2022 /PRNewswire/ -- ManaMed strives to be at the forefront of medical innovation, which is why it is excited to announce that its DVT prevention device, PlasmaFlow, has just received UnitedHealthcare coverage.
  • PlasmaFlow is a wearable and portable prescription device that helps prevent blood clots during surgery, at discharge, and at home.
  • With PlasmaFlow, ManaMed is confident that it can make a difference in the lives of those who need it most.
  • It has been in the market for over 6 years and nearly one million patients have benefited from this medical device.

Teleflex launches new Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Retrieved on: 
星期一, 六月 13, 2022
Emergency medicine, ANZ, Radiology, TFX, Pressure, Annual report, Urology, Security (finance), U.S. Securities and Exchange Commission, Solution, Venous stasis, LMA, Prostatic urethral lift, GLOBE, Patient, Risk, Health, NYSE, INS, Weck, Patient safety, Anesthesia, Teleflex, Medical device, Medical imaging, Arrow, QuikClot

WAYNE, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Australia and New Zealand.

Key Points: 
  • WAYNE, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Australia and New Zealand.
  • The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety.
  • The new, 20 cm Arrow Pressure Injectable Midline with brightly coloured yellow hubs and labeling, will help clinicians overcome catheter identification confusion, which can lead to infusion mistakes that can harm patients.
  • We are excited to bring the Arrow Pressure Injectable Midline catheter to the market here in Australia and New Zealand, and to provide an expanded product portfolio that addresses various vascular access needs.

Teleflex launches new Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region

Retrieved on: 
星期二, 六月 7, 2022
Emergency medicine, Radiology, TFX, Pressure, Annual report, Urology, Partnership, Security (finance), U.S. Securities and Exchange Commission, Solution, Venous stasis, LMA, Health, Prostatic urethral lift, GLOBE, Patient, Risk, EMEA, NYSE, INS, Patient safety, Anesthesia, Teleflex, Medical device, Medical imaging, Arrow, QuikClot

WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region.

Key Points: 
  • WAYNE, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced the launch of an Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region.
  • The addition of the pressure injectable catheter further enhances the Midline portfolio to meet the expanded needs of clinicians and is designed to improve patient safety.
  • The new, 20cm Arrow Pressure Injectable Midline with brightly colored yellow hubs and labeling, will help clinicians overcome catheter identification confusion, which can lead to infusion mistakes that can harm patients.
  • The new Arrow Pressure Injectable Midline allows for pressure injection up to 5 mL/second through either lumen to mitigate diagnostic and treatment delays of having to replace a secondary device.

Venclose MAVEN Earns FDA Clearance to Treat Incompetent Perforator Veins

Retrieved on: 
星期四, 十月 7, 2021
CVI, CE marking, IPV, Health, Leg, SAN, Vein, Temperature, Physician, Maven, Virtual private server, FDA, RFA, Radiofrequency ablation, Varicose veins, Venous stasis, FACC, CEO, Solution, Patient, Chronic venous insufficiency, Interventional cardiology, Medical device, Medical imaging

SAN JOSE, Calif., Oct. 7, 2021 /PRNewswire/ -- Venclose Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease today announced FDA 510(k) clearance for Venclose Maven, a novel radiofrequency ablation (RFA) catheter for minimally invasive treatment of incompetent perforator veins (IPVs).The Venclose Maven catheter represents Venclose's commitment to developing next-generation venous treatment solutions that help physicians provide more comprehensive patient care.

Key Points: 
  • SAN JOSE, Calif., Oct. 7, 2021 /PRNewswire/ -- Venclose Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease today announced FDA 510(k) clearance for Venclose Maven, a novel radiofrequency ablation (RFA) catheter for minimally invasive treatment of incompetent perforator veins (IPVs).The Venclose Maven catheter represents Venclose's commitment to developing next-generation venous treatment solutions that help physicians provide more comprehensive patient care.
  • "While our existing Venclose RF Ablation System, including the proprietary Venclose Catheter, continues to displace older technology for treating incompetent truncal veins, Venclose Maven will now allow doctors to also address refluxing perforators, a separate category of veins that contributes to more advanced and serious venous disease symptoms including painful venous stasis leg ulcers,"said Jerry Gibson, Venclose Chairman and CEO.
  • Like Venclose's flagship catheter, the Venclose Maven is engineered to facilitate vein wall contact via both segmental and circumferential thermal delivery.
  • Dr Hamilton added, "The Venclose Maven is a lot easier to work with and seems much better tolerated by my patients.

Insights into the Global Deep Vein Thrombosis (DVT) Market (2018 to 2026) - Opportunity Analysis for New Entrants - ResearchAndMarkets.com

Retrieved on: 
星期一, 三月 23, 2020
Medical devices, Health, Medical specialties, Angiology, Hematology, Medicine, Deep vein thrombosis, Thrombosis, Venous thrombosis, Deep vein, Superficial thrombophlebitis, Venous stasis

The "Global Deep Vein Thrombosis (DVT) Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Deep Vein Thrombosis (DVT) Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Deep Vein Thrombosis (DVT) Market is poised to grow at a CAGR of around 10.5% over the next decade during 2018 to 2026.
  • Deep vein thrombosis (DVT) is the blood clot that develops in the deep veins of the body.
  • Moreover, advancements in the field of healthcare and increasing government initiatives are the opportunities for the deep vein thrombosis (DVT) market.

PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers

Retrieved on: 
星期一, 十月 14, 2019
Health, Surgery, Stem cells, Genetics, Clinical trials, Biotechnology, Medicine, Clinical medicine, Medical specialties, Vascular diseases, Venous ulcer, Wound, Ulcer, Venous stasis, PolarityTE®, SkinTE™

The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.

Key Points: 
  • The clinical outcomes were reported in a poster presentation, entitled Pilot Study Assessing Novel Autologous Homologous Skin Construct Treatment of Venous Stasis Leg Ulcers, at the Symposium on Advanced Wound Care (SAWC) Fall Meeting, held in Las Vegas, October 12-14, 2019.
  • The pilot study included 10 patients with VLUs that remained open after at least one month of conventional treatments.
  • The study found an 80 percent closure rate of the VLUs within 12 weeks after treatment with SkinTE.
  • POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005320/en/